CRISPR Therapeutics AG CRSP
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
CRISPR Therapeutics AG (CRSP) Core Market Data and Business Metrics
Latest Closing Price
$34.19Price-Earnings Ratio
-7.88Total Outstanding Shares
85.77 Million SharesDividend
No dividendSIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
Baarerstrasse 14, Zug, V8, CH-6300
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 1,691,868 Shares | 12 | 3/14/2025 | 20,307,836 Shares |
| 2,762,173 Shares | 7.53 | 2/28/2025 | 20,808,121 Shares |
| 2,657,292 Shares | 7.68 | 2/14/2025 | 20,407,467 Shares |
| 2,080,983 Shares | 9.37 | 1/31/2025 | 19,491,883 Shares |
| 1,803,942 Shares | 11.26 | 1/15/2025 | 20,311,420 Shares |
| 1,799,431 Shares | 10.61 | 12/31/2024 | 19,097,155 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities | $-142.77 Million |
| Net Cash Flow From Investing Activities | $-280.48 Million |
| Net Cash Flow From Investing Activities, Continuing | $-280.48 Million |
| Net Cash Flow, Continuing | $-91.27 Million |
| Net Cash Flow From Financing Activities, Continuing | $331.98 Million |
| Net Cash Flow | $-91.27 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Basic Earnings Per Share | $-4.34 |
| Net Income/Loss | $-366.25 Million |
| Income Tax Expense/Benefit | $3.59 Million |
| Income Tax Expense/Benefit, Deferred | $-484,000 |
| Nonoperating Income/Loss | $103.90 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $-73,000 |
| Comprehensive Income/Loss Attributable To Parent | $-366.32 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss Attributable To Parent | $-73,000 |
| Comprehensive Income/Loss | $-366.32 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Current Assets | $1.94 Billion |
| Assets | $2.24 Billion |
| Noncurrent Liabilities | $222.17 Million |
| Equity | $1.93 Billion |
| Other Non-current Assets | $170.81 Million |
| Noncurrent Assets | $304.90 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||